Quoc Le-Nguyen
Directeur Technique/Scientifique/R&D chez 89BIO, INC.
Fortune : 2 M $ au 30/04/2024
Postes actifs de Quoc Le-Nguyen
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
| 89BIO, INC. | Directeur Technique/Scientifique/R&D | 01/03/2019 | - |
Historique de carrière de Quoc Le-Nguyen
Anciens postes connus de Quoc Le-Nguyen
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
| CHINOOK THERAPEUTICS, INC. | Corporate Officer/Principal | 01/09/2015 | 01/07/2018 |
| BAYER AG | Corporate Officer/Principal | 01/09/2007 | 01/09/2013 |
Formation de Quoc Le-Nguyen
| University of California | Undergraduate Degree |
Statistiques
Internationale
| Etats-Unis | 4 |
| Allemagne | 2 |
Opérationnelle
| Corporate Officer/Principal | 2 |
| Chief Tech/Sci/R&D Officer | 1 |
| Undergraduate Degree | 1 |
Sectorielle
| Health Technology | 4 |
| Consumer Services | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| 89BIO, INC. | Health Technology |
| BAYER AG | Health Technology |
| Entreprise privées | 1 |
|---|---|
Aduro BioTech, Inc.
 Aduro BioTech, Inc. Pharmaceuticals: MajorHealth Technology Aduro BioTech, Inc. is a clinical-stage immunotherapy company, which engages in the discovery, development, and commercialization of therapies that transform the treatment of diseases, including cancer. Its technology platforms include STING Pathway Activator, B-select monoclonal antibody, and LADD, or Live, Attenuated, Double-Deleted Listeria monocytogenes. The company's platforms stimulate and/or regulate innate and adaptive immune responses, either as single agents or in combination with conventional therapies like chemotherapy and radiation as well as other novel immunotherapies. Aduro BioTech was founded in 2000 and is headquartered in Berkeley, CA. | Health Technology |
- Bourse
- Insiders
- Quoc Le-Nguyen
- Expérience
